Status:

UNKNOWN

RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)

Lead Sponsor:

Association des Gastroentérologues Oncologues

Collaborating Sponsors:

Hôpital Européen George Pompidou, APHP, Paris, France

UMR-S1147, Université Paris Descartes

Conditions:

Metastatic Colorectal Cancer

Eligibility:

All Genders

18+ years

Brief Summary

Some data have suggested a clinical survival benefit related to the reintroduction of anti-EGFRs therapy in patients with metastatic colorectal cancer (mCRC). Based on resistance mechanisms related to...

Detailed Description

Somatic mutations in KRAS exon 2 are considered as a predictive marker of lack of efficacy for anti-EGFR therapy (panitumumab or cetuximab) in patients with metastatic colorectal cancer. Recently, it ...

Eligibility Criteria

Inclusion

  • Age ≥18 years
  • Metastatic colorectal cancer histological confirmed without somatic mutations of KRAS (exons 2, 3 et 4) and NRAS (exons 2, 3 et 4)
  • Apart from contraindication, patients should have already received fluoropyrimidine, irinotecan, oxaliplatin, anti-EGFR (panitumumab or cetuximab) and anti-angiogenic (bevacizumab or aflibercept) therapies
  • Previous treatment with anti-EGFR-based chemotherapy (panitumumab or cetuximab) should have provided an objective tumor response (according to RECIST 1.1 criteria) and/or PFS ≥ 4 months.
  • At least one line of interval chemotherapy between the last cycle of anti-EGFR based treatment and reintroduction of anti-EGFR therapy
  • Signed written informed consent obtained prior to any study specific screening procedures

Exclusion

  • Discontinuation of first anti-EGFR therapy for other reasons than tumor progression
  • Previous malignancy other than colorectal cancer in the last 5 years
  • Medical, sociological, psychological or legal conditions that would not permit the patient to sign the informed consent

Key Trial Info

Start Date :

October 1 2017

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2020

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT03259009

Start Date

October 1 2017

End Date

June 1 2020

Last Update

September 11 2017

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.